Pharmaceutical Firm and Solve.Care Partner to Develop Blockchain Network for Helping Diabetics
- Pharmaceutical firm Boehringer Ingelheim to work with Solve.care to develop distributed ledger technology (DLT)-enabled solution for diabetes patients.
- The DLT-powered software is reportedly being developed to improve data sharing, while also enhancing various other processes related to patient care for diabetes patients.
A recent announcement revealed plans for a distributed ledger technology (DLT)-based network that would better healthcare reports Cointelegraph. In particular, Germany-headquartered pharmaceutical company, Boehringer Ingelheim has partnered with blockchain-focused healthcare platform, Solve.Care for said service, which is tailored to meet the needs of diabetic patients and promoted data sharing.
Diabetes Care Administration Network (DCAN)
Details regarding the partnership was supposedly shared with the news outlet, in which it was disclosed that the network being developed will be called, ‘Diabetes Care Administration Network (DCAN).’ Besides data sharing being an aim for the project, the DCAN will also serve as an educational and communicative platform.
More specifically, users will learn about the condition along with facts on remaining healthy and also have something to rely on in terms of finding the right practitioner or acquiring the help needed. The assistance aspect of this respective network will be founded on Solve.Care’s care system, ‘Care.Wallets.’
The team at Solve.Care has also taken the time to update consumers on the endeavor. The CEO, Pradeep Goel has reasoned that this partnership would,
“help bridge a knowledge gap by providing a platform which offers vital information on diabetes and cardiovascular diseases in an easily accessible manner.”
“Most Innovative Patient-Centric Network In The World”
Goel has also expressed gratitude in being able to work alongside the German pharma company considering that it is a global leader in offering innovative solutions. He remarked:
“We are honored by [Boehringer Ingelheim’s] trust and multi-year commitment to launching one of the most innovative patient-centric networks in the world.”
The VP at Boehringer Ingelheim, Graham Goodrich has since expressed a similar sentiment, emphasizing on the significance of the DCAN:
“Recent changes to diabetes treatment recommendations have prioritized managing cardiovascular risk and this program will help ensure both patients and providers are proactively addressing life-threatening conditions […]”
As for the launch of the DCAN, the duo has since set a soft timeframe – indicating that it would take place either at year end or closer in range.